|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRCC |
Gene summary for PRCC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRCC | Gene ID | 5546 |
| Gene name | proline rich mitotic checkpoint control factor | |
| Gene Alias | RCCP1 | |
| Cytomap | 1q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0007049 | UniProtAcc | A0A0S2Z456 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5546 | PRCC | LZE2T | Human | Esophagus | ESCC | 6.48e-07 | 3.46e-01 | 0.082 |
| 5546 | PRCC | LZE4T | Human | Esophagus | ESCC | 4.37e-17 | 3.30e-01 | 0.0811 |
| 5546 | PRCC | LZE7T | Human | Esophagus | ESCC | 5.22e-10 | 8.10e-01 | 0.0667 |
| 5546 | PRCC | LZE8T | Human | Esophagus | ESCC | 5.52e-06 | 1.98e-01 | 0.067 |
| 5546 | PRCC | LZE20T | Human | Esophagus | ESCC | 7.17e-09 | 2.21e-01 | 0.0662 |
| 5546 | PRCC | LZE22D1 | Human | Esophagus | HGIN | 1.34e-04 | 8.70e-02 | 0.0595 |
| 5546 | PRCC | LZE22T | Human | Esophagus | ESCC | 6.55e-07 | 4.16e-01 | 0.068 |
| 5546 | PRCC | LZE24T | Human | Esophagus | ESCC | 1.39e-23 | 5.54e-01 | 0.0596 |
| 5546 | PRCC | LZE21T | Human | Esophagus | ESCC | 1.03e-05 | 4.16e-01 | 0.0655 |
| 5546 | PRCC | LZE6T | Human | Esophagus | ESCC | 7.30e-09 | 6.15e-01 | 0.0845 |
| 5546 | PRCC | P1T-E | Human | Esophagus | ESCC | 1.87e-14 | 6.20e-01 | 0.0875 |
| 5546 | PRCC | P2T-E | Human | Esophagus | ESCC | 4.00e-43 | 7.89e-01 | 0.1177 |
| 5546 | PRCC | P4T-E | Human | Esophagus | ESCC | 2.34e-26 | 5.73e-01 | 0.1323 |
| 5546 | PRCC | P5T-E | Human | Esophagus | ESCC | 2.70e-28 | 5.54e-01 | 0.1327 |
| 5546 | PRCC | P8T-E | Human | Esophagus | ESCC | 2.66e-24 | 4.28e-01 | 0.0889 |
| 5546 | PRCC | P9T-E | Human | Esophagus | ESCC | 4.57e-27 | 6.22e-01 | 0.1131 |
| 5546 | PRCC | P10T-E | Human | Esophagus | ESCC | 1.49e-32 | 6.12e-01 | 0.116 |
| 5546 | PRCC | P11T-E | Human | Esophagus | ESCC | 7.48e-21 | 8.05e-01 | 0.1426 |
| 5546 | PRCC | P12T-E | Human | Esophagus | ESCC | 9.51e-23 | 4.95e-01 | 0.1122 |
| 5546 | PRCC | P15T-E | Human | Esophagus | ESCC | 4.20e-45 | 9.86e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0521118 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
| hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
| hsa0521119 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
| hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
| hsa052116 | Liver | Cirrhotic | Renal cell carcinoma | 33/2530 | 69/8465 | 1.24e-03 | 6.64e-03 | 4.09e-03 | 33 |
| hsa0521111 | Liver | Cirrhotic | Renal cell carcinoma | 33/2530 | 69/8465 | 1.24e-03 | 6.64e-03 | 4.09e-03 | 33 |
| hsa0521121 | Liver | HCC | Renal cell carcinoma | 51/4020 | 69/8465 | 6.76e-06 | 5.53e-05 | 3.07e-05 | 51 |
| hsa0521131 | Liver | HCC | Renal cell carcinoma | 51/4020 | 69/8465 | 6.76e-06 | 5.53e-05 | 3.07e-05 | 51 |
| hsa0521116 | Oral cavity | OSCC | Renal cell carcinoma | 51/3704 | 69/8465 | 3.30e-07 | 2.05e-06 | 1.04e-06 | 51 |
| hsa0521117 | Oral cavity | OSCC | Renal cell carcinoma | 51/3704 | 69/8465 | 3.30e-07 | 2.05e-06 | 1.04e-06 | 51 |
| hsa0521125 | Oral cavity | LP | Renal cell carcinoma | 30/2418 | 69/8465 | 5.60e-03 | 2.25e-02 | 1.45e-02 | 30 |
| hsa0521135 | Oral cavity | LP | Renal cell carcinoma | 30/2418 | 69/8465 | 5.60e-03 | 2.25e-02 | 1.45e-02 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRCC | SNV | Missense_Mutation | novel | c.1054G>A | p.Asp352Asn | p.D352N | Q92733 | protein_coding | tolerated(0.11) | possibly_damaging(0.642) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| PRCC | SNV | Missense_Mutation | c.827T>G | p.Phe276Cys | p.F276C | Q92733 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
| PRCC | SNV | Missense_Mutation | rs541774348 | c.616N>T | p.Arg206Cys | p.R206C | Q92733 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-BH-A6R8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PRCC | SNV | Missense_Mutation | novel | c.347G>T | p.Arg116Leu | p.R116L | Q92733 | protein_coding | tolerated(0.1) | benign(0) | TCGA-E2-A15T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| PRCC | SNV | Missense_Mutation | c.166N>G | p.Gln56Glu | p.Q56E | Q92733 | protein_coding | tolerated_low_confidence(0.13) | possibly_damaging(0.585) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| PRCC | SNV | Missense_Mutation | rs746351796 | c.41N>T | p.Pro14Leu | p.P14L | Q92733 | protein_coding | deleterious_low_confidence(0) | benign(0.103) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| PRCC | SNV | Missense_Mutation | c.166C>G | p.Gln56Glu | p.Q56E | Q92733 | protein_coding | tolerated_low_confidence(0.13) | possibly_damaging(0.585) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| PRCC | SNV | Missense_Mutation | c.506C>A | p.Thr169Asn | p.T169N | Q92733 | protein_coding | tolerated(0.67) | benign(0.005) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PRCC | SNV | Missense_Mutation | novel | c.1282N>C | p.Lys428Gln | p.K428Q | Q92733 | protein_coding | tolerated(0.09) | benign(0.203) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| PRCC | SNV | Missense_Mutation | novel | c.1403N>C | p.Glu468Ala | p.E468A | Q92733 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |